Clinical Trial Update: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for ABBV-319 evaluating adverse events, change in disease activity, and pharmacokinetics in adults with relapsed or refractory DLB…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• ABBV-319

Snippet

Sponsor: AbbVie | Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: RECRUITING